Tracers / [89Zr]trastuzumab-PEG6-DM1
[89Zr]trastuzumab-PEG6-DM1
Also written as [Zr-89]Zr-trastuzumab-PEG6-DM1
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Antibody-drug conjugate (trastuzumab-PEG6-DM1, HER2-targeting)
- Target / mechanism
- HER2 (domain IV targeting antibody-drug conjugate) PMID 37095184
- Clinical application
- Breast cancer theranostics (biparatopic anti-HER2 drug radioconjugates) PMID 37095184
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | trastuzumab-PEG6-DM1 | 37095184 2023 Br J Cancer |
Need this precursor?We can point you to suppliers for [89Zr]trastuzumab-PEG6-DM1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37095184. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37095184: 'trastuzumab-PEG6-DM1 (domain IV) and pertuzumab-PEG6-DM1 (domain II) were developed, characterised and radiolabeled to obtain [89Zr]Zr-trastuzumab-PEG6-DM1'.